{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"Verbesserung der Versorgungsqualit&#228;t durch standardisierte Dokumentation d-uo VERSUS","eudractNumber":null,"id":10722,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-11T08:36:50+01:00","shortTitle":"Versus","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":9618,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-02-23T10:10:34+01:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":7969,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-06-01T10:03:16+02:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wirksamkeit\n/ Effekte einer Yogatherapie bei Patienten mit hirneigenem Tumor WHO&#176; Grad III\nund IV und deren Angeh&#246;rigen<div><br /></div><div><b>DRKS00029554</b><br /></div><div><b><br /></b></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":4430,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2019-02-01T10:53:27+01:00","shortTitle":"YINOTA-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Effekte von Yoga auf Angst, Unruhe, Schlafqualit&#228;t und Fatigue bei Frauen mit der Erstdiagnose Brustkrebs &#8211; eine randomisierte kontrollierte Studie","eudractNumber":null,"id":10894,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-01-01T10:53:43+01:00","shortTitle":"Yoga-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">Molekulare Erregerdiagnostik und Untersuchungen zu\nSARS-CoV-2 bei Patienten mit ZNS-St&#246;rung nach h&#228;matopoetischer\nStammzelltransplantation und gesunden Probanden</p><p class=\"MsoNormal\" style=\"line-height:normal;\">DRKS00029343&#160;(keine weiteren Registriernummern)</p>","eudractNumber":null,"id":10388,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-08-16T07:00:05+02:00","shortTitle":"ZNMoDiSZ","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilt-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in combination with Daratumumab SC (Tec-D) Following Induction with Daratumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnose Multiple Myeloma","eudractNumber":"2023-505792-71","id":9857,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-05-08T11:47:58+02:00","shortTitle":"aMMbition","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA</div>","eudractNumber":"2019-004153-93","id":9005,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-12-04T08:59:33+01:00","shortTitle":"i EuroEwing","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"International Registry of the HIT-HGG Study Group for Paediatric Patients and Young Adults with High Grade Gliomas","eudractNumber":null,"id":10796,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-01-01T14:06:32+01:00","shortTitle":"iHIT-HGG Registry","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"&#160;A Phase 3, Randomized, Open Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with relapesd, refractory Multiple Myeloma (KT-US-679-0788,&#160;iMMagine-3)","eudractNumber":"2024-511188-26","id":9859,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06413498","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-06-13T12:34:08+02:00","shortTitle":"iMMagine-3","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}